Allakos Inc

NASDAQ ALLK

Download Data

Allakos Inc Quick Ratio 3 year CAGR for the quarter ending September 19, 2024

Allakos Inc Quick Ratio 3 year CAGR is NA for the quarter ending September 19, 2024. The quick ratio, also known as the acid-test ratio, measures a company's ability to meet its short-term obligations using its most liquid assets. It is calculated by dividing the current assets minus inventory by the current liabilities. This ratio provides insights into the company's liquidity position and its ability to pay off current liabilities without relying on inventory sales. A higher ratio suggests a stronger ability to meet short-term obligations with readily available assets. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
NASDAQ: ALLK

Allakos Inc

CEO Dr. Robert Alexander Ph.D.
IPO Date July 19, 2018
Location United States
Headquarters 975 Island Drive, Redwood City, CA, United States, 94065
Employees 131
Sector Healthcare
Industry Biotechnology
Description

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

CRBU

Caribou Biosciences Inc

NA

NA

KURA

Kura Oncology Inc

NA

NA

NXTC

NextCure  Inc

NA

NA

GTHX

G1 Therapeutics Inc

NA

NA

HRTX

Heron Therapeuti

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email